Nifty 17196.7 (-1.18%)
Sensex 57767.1 (-1.19%)
Nifty Bank 36197.15 (-0.85%)
Nifty IT 35829.25 (-0.91%)
Nifty Financial Services 17776.7 (-1.15%)
Adani Ports 736.80 (-0.31%)
Asian Paints 3115.00 (-2.06%)
Axis Bank 672.75 (-0.50%)
B P C L 386.00 (1.89%)
Bajaj Auto 3287.00 (-1.24%)
Bajaj Finance 7085.00 (-1.33%)
Bajaj Finserv 17501.25 (-1.45%)
Bharti Airtel 718.20 (-1.96%)
Britannia Inds. 3552.00 (-0.74%)
Cipla 912.75 (-0.92%)
Coal India 159.85 (0.35%)
Divis Lab. 4751.00 (-0.55%)
Dr Reddys Labs 4595.00 (-1.45%)
Eicher Motors 2456.00 (0.18%)
Grasim Inds 1702.00 (-1.27%)
H D F C 2777.00 (-1.10%)
HCL Technologies 1170.40 (-1.21%)
HDFC Bank 1514.00 (-0.77%)
HDFC Life Insur. 691.00 (-2.03%)
Hero Motocorp 2465.00 (-0.31%)
Hind. Unilever 2348.50 (-1.46%)
Hindalco Inds. 424.90 (-1.67%)
I O C L 122.40 (1.45%)
ICICI Bank 717.15 (-0.73%)
IndusInd Bank 952.60 (0.75%)
Infosys 1737.60 (-0.61%)
ITC 221.50 (-1.75%)
JSW Steel 646.00 (-0.12%)
Kotak Mah. Bank 1920.00 (-2.25%)
Larsen & Toubro 1800.00 (0.60%)
M & M 835.95 (-1.60%)
Maruti Suzuki 7200.00 (-1.71%)
Nestle India 19320.00 (-0.94%)
NTPC 127.00 (-1.32%)
O N G C 145.80 (1.25%)
Power Grid Corpn 205.80 (-4.06%)
Reliance Industr 2413.15 (-2.81%)
SBI Life Insuran 1165.00 (-1.94%)
Shree Cement 25860.05 (-1.63%)
St Bk of India 471.95 (-1.06%)
Sun Pharma.Inds. 753.00 (-1.73%)
Tata Consumer 774.80 (0.20%)
Tata Motors 480.30 (0.25%)
Tata Steel 1114.65 (0.20%)
TCS 3641.00 (-0.05%)
Tech Mahindra 1598.90 (-1.89%)
Titan Company 2376.45 (-0.42%)
UltraTech Cem. 7344.40 (0.29%)
UPL 713.00 (2.12%)
Wipro 640.45 (-0.98%)
INFY

Mangalam Drugs and Organi..

₹124.05
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

As per analysts rating in the last 6 months, the recommendation is to HOLD Mangalam Drugs

  • Master Rating:
  • Mangalam Drugs & Orgs. has an operating revenue of Rs. 398.45 Cr. on a trailing 12-month basis. An annual revenue growth of 36% is outstanding, Pre-tax margin of 10% is healthy, ROE of 21% is exceptional. The company has a reasonable debt to equity of 5%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 11 which is a POOR score indicating inconsistency in earnings, a RS Rating of 11 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 149 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Mangalam Drugs and Organics Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Mangalam Drugs and Organics Ltd Synopsis

NSE-Medical-Generic Drugs

Mangalam Drugs is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 380.14 Cr. and Equity Capital is Rs. 15.83 Cr. for the Year ended 31/03/2021. Mangalam Drugs and Organics Ltd. is a Public Limited Listed company incorporated on 18/04/1972 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1972PLC116413 and registration number is 116413.
  • Market Cap

    INR 199.43 Cr

  • Sales

    INR 398.45 Cr

  • Shares in Float

    0.78 Cr

  • No of Funds

    4 K

  • Yield

    0.68%

  • Book Value

    1.5

  • U/D Vol Ratio

    1.1

  • LTDebt/Equity

    5%

  • Alpha

    -0.09

  • Beta

    0.74

Mangalam Drugs and Organics Ltd Ownership
Mangalam Drugs and Organics Ltd Management

Mangalam Drugs and Organics Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 130.9619103.938795.6631103.766585.7172
Fixed Assets Annual Cr 118.435102.3095103.6914101.980592.5562
Total Non Current Assets Annual Cr 130.8706111.4923106.3153103.945993.7189
Total Current Assets Annual Cr 131.9771119.1748105.0396122.841595.7849
Total Assets Annual Cr 262.8477230.6671211.3549226.7874189.5038
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 65.66660.43865.55754.154
ROE Annual % 7.93-8.3919.1625.98
ROCE Annual % 13.742.4132.3936.88
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 15.268.84.3917.0715.26

Mangalam Drugs and Organics Ltd Technicals

EMA & SMA

CURRENT PRICE

124.05 (0.04)

    • Bullish Moving Averages 1
    • Bearish Moving Averages 15

EMA

  • 20 Day

    129.45

  • 50 Day

    136.24

  • 100 Day

    139.4

  • 200 Day

    137.78

Mangalam Drugs and Organics Ltd Resistance and support

124.45 PIVOT

  • First Resistance

    125.5

  • Second Resistance

    127

  • Third Resistance

    128.06

  • First Support

    122.95

  • Second Support

    121.9

  • Third Support

    120.4

  • RSI

    35.64

  • MFI

    12.84

  • MACD

    -4.44

  • MACD signal line

    -4.1

Mangalam Drugs and Organics Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 15,744 940,861 59.76%
Week 39,685 2,183,855 55.03%
1 Month 41,414 2,440,965 58.94%
6 Month 188,710 8,656,112 45.87%

Mangalam Drugs and Organics Ltd Price change analysis

-10.75

Over 1 month

Low High
117.55 148

-22.15

Over 3 month

Low High
117.55 157.5

-11.45

Over 6 months

Low High
117.55 196.95

-23.2

Over Year

Low High
91 196.95

Similar Stocks

News

Mangalam Drugs & Organics Ltd - 532637 - Disclosures under R

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2 Read More

Mangalam Drugs & Organics Ltd - 532637 - Disclosures under R

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2 Read More

Mangalam Drugs & Organics Ltd - 532637 - Standalone Un-Audit

Pursuant to Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (th Read More

MANGALAM DRUGS & ORGANICS LTD. - 532637 - Board Meeting Outc

Pursuant to Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (th Read More

Mangalam Drugs & Organics Ltd - 532637 - Disclosures under R

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2 Read More

Blogs

FAQs